Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Virtual Reality-Supported Autism Education for Nursing Students (VR-AUTISM-NURS)

12 novembre 2026 aggiornato da: Edanur Tar Bolacali, Kirsehir Ahi Evran Universitesi

Effect of a Virtual Reality-Supported Autism Education Program for Nursing Students on Autism-Related Knowledge, Awareness, and Attitudes: A Randomized Controlled Trial

The goal of this clinical trial is to learn if a virtual reality (VR)-supported autism education program improves knowledge, awareness, and attitudes about autism spectrum disorder (ASD) in fourth-year nursing students. The main questions it aims to answer are:

  • Does the program increase nursing students' knowledge of autism?
  • Does the program increase their awareness of autism and improve their attitudes toward people with autism?

Researchers will compare students who take the program with students who receive no education during the study, to see if the program improves knowledge, awareness, and attitudes, and whether these effects last one month after the program.

Participants will:

  • Attend one 90-minute face-to-face session per week for 8 weeks (education group only). Sessions in weeks 1 to 7 use active learning methods such as group work and brainstorming. In week 8, each student watches a short (about 5-minute) 360-degree VR scenario that shows a hospital visit from the point of view of a child with autism, followed by a guided group discussion.
  • Complete questionnaires on autism knowledge, awareness, and attitudes before the program, after the program (week 8), and one month later.

Students in the control group will be offered the same program after the study ends.

Panoramica dello studio

Descrizione dettagliata

Background: Nurses working in primary care and child health services are in a key position to recognize early signs of autism spectrum disorder (ASD) and to refer children for timely assessment. However, nursing students often report limited knowledge and low confidence in this area. Immersive virtual reality (VR) allows learners to experience sensory and social situations from the perspective of a child with autism without involving children in the teaching process.

Design: This is a single-center, two-arm, parallel-group, open-label randomized controlled trial with pretest, posttest, and one-month follow-up measurements. The study will be reported according to CONSORT and the CONSORT-Outcomes 2025 extension.

Randomization: After baseline measurement, participants will be allocated 1:1 by simple randomization using a computer-generated sequence (randomizer.org). Randomization will be performed by an independent researcher not involved in delivering the intervention, and the allocation list will be concealed from the research team until assignment is complete. Data will be coded by group (Group A/Group B) and analyzed by a statistician blinded to group allocation.

Intervention content: Weekly modules cover the diagnostic framework of ASD, social communication and interaction, restricted and repetitive behaviors, sensory experience and perspective taking, comorbidities and differential diagnosis, the nurse's role in early identification and referral, and stigma and professional attitudes. Teaching methods include station rotation, six thinking hats, brainstorming, the six-shoe technique, and cooperative learning (inner-outer circle). Week 8 is a simulation session ("A Journey into the World of a Child with Autism") in which students experience an 8-year-old child's hospital visit first in an unadapted and then in an autism-friendly environment, followed by a structured debriefing. Content will be reviewed by autism experts and piloted with nursing students before the trial.

Statistical analysis: Group-by-time effects across the three measurements will be analyzed with two-way repeated-measures ANOVA, or the nonparametric F1-LD-F1 model if assumptions are not met. Analyses will follow the intention-to-treat principle, and missing data will be handled by multiple imputation. Effect sizes (Cohen's d, partial eta squared) will be reported. The significance level is p<0.05.

Tipo di studio

Interventistico

Iscrizione (Stimato)

80

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Fourth-year student in the Department of Nursing, Faculty of Health Sciences, Kirsehir Ahi Evran University
  • Has completed the pediatric (child health and diseases) nursing course
  • Has not previously attended a structured education program on autism spectrum disorder
  • Agrees to participate voluntarily and signs the informed consent form
  • Is able to attend the education sessions and measurements

Exclusion Criteria:

  • Known health condition that may prevent the use of virtual reality (e.g., severe motion sickness or vertigo, epilepsy)
  • Not completing the baseline (pretest) measurements

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: VR-Supported Autism Education

Participants will attend an 8-week modular autism education program with one 90-minute face-to-face session per week. Weeks 1-7 consist of active learning modules on autism spectrum disorder. Week 8 consists of a virtual reality simulation session followed by a structured debriefing.

An 8-week program with one 90-minute face-to-face session per week. Weeks 1-7 cover the diagnostic framework of autism spectrum disorder, social communication and interaction, restricted and repetitive behaviors, sensory experience and perspective taking, comorbidities and differential diagnosis, the nurse's role in early identification and referral, and stigma and professional attitudes, using station rotation, six thinking hats, brainstorming, six-shoe technique, and cooperative learning methods. In week 8, each student experiences an approximately 5-minute immersive 360-degree VR scenario of an 8-year-old child's hospital visit from the child's perspective, first in an unadapted and then in an autism-friendly environment, followed by a structured debriefing.

Nessun intervento: Control

Participants will receive no education during the study period and will complete the same questionnaires at the same time points (baseline, week 8, and week 12). They will be offered the same education program after the follow-up measurement.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Autism Knowledge Score (Knowledge about Childhood Autism among Health Workers Questionnaire)
Lasso di tempo: Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Autism knowledge will be measured with the Turkish version of the Knowledge about Childhood Autism among Health Workers (KCAHW) Questionnaire. It has 19 items covering social interaction, communication, behavioral patterns, and features of the disorder. Each correct answer scores 1 and each incorrect or "don't know" answer scores 0, giving a total score of 0 to 19. Higher scores indicate greater knowledge of childhood autism.

Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Autism Awareness Score (Autism Awareness Scale)
Lasso di tempo: Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Autism awareness will be measured with the Autism Awareness Scale, which has 32 items in 7 subscales (restricted interests and repetitive behaviors, social interaction and communication, causes of autism, peer relationships, key elements of intervention, physical characteristics, and early warning signs). Items are rated on a 5-point Likert scale (1 = strongly disagree, 5 = strongly agree), with reverse-scored items, giving a total score of 32 to 160. Higher scores indicate greater awareness of autism.

Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)
Attitudes Toward Autism Score (Societal Attitudes Towards Autism Scale)
Lasso di tempo: Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Attitudes toward autism will be measured with the Turkish version of the Societal Attitudes Towards Autism (SATA) Scale, which has 26 items in 3 subscales (personal distance, knowledge, and social life). Items are rated on a 4-point scale, with reverse-scored items, giving a total score of 26 to 104. Higher scores indicate more positive attitudes toward individuals with autism.

Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

17 novembre 2026

Completamento primario (Stimato)

15 gennaio 2027

Completamento dello studio (Stimato)

28 febbraio 2027

Date di iscrizione allo studio

Primo inviato

12 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be shared publicly because participants were informed in the consent process that their data would be used only by the research team for scientific purposes. Aggregate results will be published in a peer-reviewed journal. De-identified data may be made available by the principal investigator upon reasonable request after publication, subject to ethics committee approval.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi